A Phase 1, Open-Label, PET Study of T2310 & BPN14770

Summary

This is a sponsor initiated, single site, first-in-human study of an investigational imaging agent for quantifying the topographically specific concentrations of the phosphodiesterase enzyme Type 4D (PDE4D) with positron emission tomography (PET) using a selective radioligand, \[11C\]T2310. T2310 will be measured with imaging techniques to characterize plasma exposure levels versus regionally specific target engagement fractions for oral doses of BPN14770, an investigational new drug (IND) for modulating PDE4D. BPN14770 is under evaluation for the treatment of Fragile X syndrome and Alzheimer's disease.

Timeline

Start

2020-01-10

Primary completion

2020-04-30

Completion

2020-05-30

Drugs

Indications

No indication recorded.